JPMorgan analyst Jessica Fye reinstated coverage of Deciphera with a Neutral rating and $14 price target. The analyst reinstated ratings, estimates and price targets for the U.S. large cap biotechnology space.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on DCPH:
- Biotech Alert: Searches spiking for these stocks today
- Deciphera price target raised to $22 from $20 at Stifel
- Deciphera price target raised to $30 from $25 at H.C. Wainwright
- Deciphera upgraded to Buy from Hold at JonesResearch
- Piper upgrades Deciphera, sees vimseltinib and Qinlock poised for upside